Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
2seventy bio (TSVT)
NASDAQ:TSVT
Holding TSVT?
Track your performance easily
TSVT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.35 - $6.40
Previous CloseN/A
Volume53.84K
Average Volume (3M)382.07K
Market Cap
$134.13M
Enterprise Value$301.73M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)$122.26M
Price to Earnings (P/E)―
Beta2.93
Next Earnings
Mar 25, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.85
Shares Outstanding51,588,420
10 Day Avg. Volume262,590
30 Day Avg. Volume382,072
Standard Deviation0.29
R-Squared0.09
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.94
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market Cap2.25
Enterprise Value/Revenue6.67
Enterprise Value/Gross Profit3.61
Enterprise Value/Ebitda-2.18
Forecast
1Y Price Target
$5.67Price Target Upside113.16% Upside
Rating ConsensusHold
Number of Analyst Covering4
2seventy bio News
PremiumCompany Announcements
2seventy bio Reports Strong Growth in Abecma Sales
PremiumCompany Announcements
2seventy bio Reports Strong Q3 with Abecma Growth
PremiumCompany Announcements
2seventy bio Halts KarMMa-9 Study, Forecasts Strong Abecma Sales
Bulls Say, Bears Say
Bulls Say
Cash Position2Seventy ended the quarter with $192 million in cash, cash equivalents, and marketable securities and reiterated a cash runway beyond 2027 and a path to profitability by 2025.
Financial Performance2Seventy Bio, Inc. reported $11M in Q3 Abecma collaborative arrangement revenue, showing a significant 150% quarter-over-quarter increase.
Sales GrowthThe company's ongoing expansion in 3L+ MM and return to Abecma at leading academic centers reflect solid growth.
Bears Say
Financial Performance2Seventy's top-line revenue fell short of expectations, reflecting Abecma's gross profit.
Market CompetitionLong-term prospects for Abecma remain unclear due to competition from superior efficacy treatments and survey results indicating limited change in outlook for Abecma.
Product PositioningAbecma’s standing as the go-to BCMA CAR-T for risk-averse or frail patients could face headwinds.
---
Ownership Overview
10.23% Insiders
11.00% Mutual Funds
<0.01% Other Institutional Investors
65.09% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TSVT FAQ
What was 2seventy bio’s price range in the past 12 months?
2seventy bio lowest stock price was $2.35 and its highest was $6.40 in the past 12 months.
What is 2seventy bio’s market cap?
2seventy bio’s market cap is $134.13M.
When is 2seventy bio’s upcoming earnings report date?
2seventy bio’s upcoming earnings report date is Mar 25, 2025 which is in 51 days.
How were 2seventy bio’s earnings last quarter?
2seventy bio released its earnings results on Nov 12, 2024. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.193 by $0.003.
Is 2seventy bio overvalued?
According to Wall Street analysts 2seventy bio’s price is currently Undervalued.
Does 2seventy bio pay dividends?
2seventy bio does not currently pay dividends.
What is 2seventy bio’s EPS estimate?
2seventy bio’s EPS estimate is -0.17.
How many shares outstanding does 2seventy bio have?
2seventy bio has 51,588,420 shares outstanding.
What happened to 2seventy bio’s price movement after its last earnings report?
2seventy bio reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.193. Following the earnings report the stock price went down -6.957%.
Which hedge fund is a major shareholder of 2seventy bio?
Currently, no hedge funds are holding shares in TSVT
---
2seventy bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.67 (113.16% Upside)
$5.67 (113.16% Upside)
Blogger Sentiment
Bullish
TSVT Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 268.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $369.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.85%
12-Months-Change
Fundamentals
Return on Equity
-35.38%
Trailing 12-Months
Asset Growth
-21.37%
Trailing 12-Months
Company Description
2seventy bio
2seventy bio Inc is primarely in the business of pharmaceutical preparations.
---
TSVT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong growth in ABECMA revenues and significant cost reductions, indicating positive progress towards breakeven. Despite seasonal challenges and market competition, the company remains optimistic about future growth and operational efficiency.Read More>---
TSVT Stock 12 Month Forecast
Average Price Target
$5.67
▲(113.16% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Sangamo Biosciences
―
Bluebird Bio
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering TSVT
1 Year
1 Year Success Rate
0/21 ratings generated profit
1 Year Average Return
-51.75%
reiterated a buy rating 2 months ago
Copying Daina Graybosch's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -51.75% per trade.
---